United States· US:47335-475_ad13dbca-474d-4492-9c25-e0e175143d8c
imatinib mesylate
A imatinib product containing imatinib mesylate, registered in United States by Sun Pharmaceutical Industries, Inc.. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Imatinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EA01 (imatinib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Imatinib · ATC L01EA01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of imatinib costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $2.80 in United States to $41.72 in Switzerland — a ×15 gap.
- United States: $2.80 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Imatinib · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- CH Switzerland$41.72
- IT Italy$11.38
- US United States$2.80 (acquisition cost)
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- imatinib mesylate
- Manufacturer
- Sun Pharmaceutical Industries, Inc.
- Country
- United States (US)
- ATC code
- L01EA01
- ATC class
- Imatinib
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 4
- ndc114733547513500 TABLET, FILM COATED in 1 BOTTLE (47335-475-13)
- ndc1147335475643 BLISTER PACK in 1 CARTON (47335-475-64) / 10 TABLET, FILM COATED in 1 BLISTER PACK
- ndc11473354758330 TABLET, FILM COATED in 1 BOTTLE (47335-475-83)
- ndc114733547588100 TABLET, FILM COATED in 1 BOTTLE (47335-475-88)
Regulatory notes
Interactions
766 interactions on record for imatinib.
Graded by severity as the source publishes them — 114 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Imatinib · interactions on record
766 records
- 114 severe
- 518 moderate
- 23 minor
- 111 info
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Imatinib in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLIVECNovartis Europharm Limited, Dublin
- NetherlandsBimatix 400 mg filmomhulde tablettenStada Arzneimittel AG
- BelgiumGlivec 400 mgPI Pharma
- FinlandBimatixSTADA Arzneimittel AG
- SwitzerlandGlivec
- SpainGLIVEC 400 mg COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- SwedenBimatix 400 mg Filmdragerad tablettSTADA Arzneimittel AG
- FranceGLIVEC 400 mg, comprimé pelliculéNOVARTIS EUROPHARM (IRLANDE)
Authorised across Europe · EMA
The same active substance is authorised in 31 EEA countries. Names it is sold under:
- Austria · Imagerolan, Imatinib 1a Pharma
- Belgium · Imatinib Eg, Imatinib Grindeks
- Bulgaria · Иматиниб Тева Фарма, Меаксин
- Cyprus · Imarem, Imatinib Koanaa 100 Mg
- Czechia · Imanivec, Imatinib Grindeks
- Germany · Imanivec, Imatinib 1 A Pharma
- Denmark · Bimatix, Imatinib "sandoz"
- Estonia · Glipox, Imatinib Grindeks
- Spain · Imatinib Cipla, Imatinib Farmalider
- Finland · Bimatix, Imatinib Hexal
- France · Imatinib Arrow Lab, Imatinib Bgr
- United Kingdom (Northern Ireland) · Imatinib, Imatinib Amarox
- Greece · Imatek, Imatinib Aenorasis
- Croatia · Imakrebin, Meaxin
- Hungary · Imaniver, Imatinib 1 A Pharma
- Ireland · Imatinib Krka D.D., Imatinib Rowex
- Iceland · Bimatix, Glivec
- Italy · Imanivec, Imatinib Dr. Reddy’s
- Liechtenstein · Glivec, Imatinib Accord
- Lithuania · Glipox, Imatinib Grindeks
- Luxembourg · Imatinib, Imatinib Eg
- Latvia · Imatinib Grindeks, Imatinib Inteli
- Malta · Imatinib Tad, Nibix
- Netherlands · Bimatix, Imakrebin
- Norway · Bimatix, Glivec
- Poland · Imatenil, Meaxin
- Portugal · Imatinib Aurobindo, Imatinib Aurovitas
- Romania · Imakrebin, Imatinib Grindeks
- Sweden · Bimatix, Imatinib Amarox
- Slovenia · Meaxin
- Slovakia · Imatinib Glenmark, Imatinib Grindeks
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ef13fa3d-5e98-47a6-b2f0-d3ae35f15e34 GET /v1/drugs/ef13fa3d-5e98-47a6-b2f0-d3ae35f15e34?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "8A1O1M485B",
"rxcui": "284924",
"inchikey": "YLMAHDNUQAMNNX-UHFFFAOYSA-N",
"display_name": "IMATINIB MESYLATE",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "ORAL",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 1
},
"spl_meta": {
"c0611fc0-b217-4988-acd4-b8c629ce489b": {
"match": "brand_token",
"title": "IMATINIB MESYLATE TABLET, FILM COATED [BLUEPOINT LABORATORIES]",
"spl_version": "4",
"published_date": "2026-05-25"
}
},
"productid": "47335-475_ad13dbca-474d-4492-9c25-e0e175143d8c",
"productndc": "47335-475",
"dosage_form": "TABLET, FILM COATED",
"orange_book": {
"appl_no": "078340",
"products": [
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "EQ 100MG BASE",
"product_no": "001",
"approval_date": "Dec 3, 2015"
},
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "EQ 400MG BASE",
"product_no": "002",
"approval_date": "Dec 3, 2015"
}
],
"appl_type": "A"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "IMATINIB MESYLATE",
"proprietary_name": "imatinib mesylate",
"active_ingred_unit": "mg/1",
"application_number": "ANDA078340",
"marketing_category": "ANDA",
"nonproprietary_name": "imatinib mesylate",
"start_marketing_date": "20160201",
"active_numerator_strength": "400"
}See everything about imatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.